Clinical Trial Update: 1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy [Phase 4]

View source ↗

Summary

A completed Phase 4 trial compared telmisartan 80 mg to valsartan 160 mg over one year in hypertensive patients with type 2 diabetes and overt nephropathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy
• Hypertension

Drugs mentioned

• DIOVAN (valsartan)
• Micardis (telmisartan)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetic Nephropathies, Hypertension | Phase 4 | Status: COMPLETED